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Abstract
Antigenic variation among circulating H5N1 highly pathogenic avian influenza A viruses mandates the continuous
production of strain-specific pre-pandemic vaccine candidates and represents a significant challenge for pandemic
preparedness. Here we assessed the structural, antigenic and receptor-binding properties of three H5N1 HPAI virus
hemagglutinins, which were recently selected by the WHO as vaccine candidates [A/Egypt/N03072/2010 (Egypt10, clade
2.2.1), A/Hubei/1/2010 (Hubei10, clade 2.3.2.1) and A/Anhui/1/2005 (Anhui05, clade 2.3.4)]. These analyses revealed that
antigenic diversity among these three isolates was restricted to changes in the size and charge of amino acid side chains at
a handful of positions, spatially equivalent to the antigenic sites identified in H1 subtype viruses circulating among humans.
All three of the H5N1 viruses analyzed in this study were responsible for fatal human infections, with the most recently-
isolated strains, Hubei10 and Egypt10, containing multiple residues in the receptor-binding site of the HA, which were
suspected to enhance mammalian transmission. However, glycan-binding analyses demonstrated a lack of binding to
human a2-6-linked sialic acid receptor analogs for all three HAs, reinforcing the notion that receptor-binding specificity
contributes only partially to transmissibility and pathogenesis of HPAI viruses and suggesting that changes in host
specificity must be interpreted in the context of the host and environmental factors, as well as the virus as a whole.
Together, our data reveal structural linkages with phylogenetic and antigenic analyses of recently emerged H5N1 virus
clades and should assist in interpreting the significance of future changes in antigenic and receptor-binding properties.
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Highly pathogenic avian influenza (HPAI) A (H5N1) viruses
have caused severe respiratory and systemic disease in humans and
feature an exceptionally high mortality rate. Continual outbreaks
of HPAI H5N1 viruses among poultry [1–3] represent a constant
threat for direct inter-species transmission to humans. More than
600 cases of human infection with H5N1 viruses have been
confirmed over the past decade [4] and, although widespread
transmission of these viruses among the human population has yet
to be reported, isolated cases of probable human-to-human
transmission have been identified [5–8]. With continuous
outbreaks of H5N1 virus among wild and domestic bird
populations across Asia, Europe, the Middle East and Africa, it
is clear why an H5N1 virus capable of sustained human
transmission remains a global public health concern [9].
All influenza viruses undergo frequent mutation in their surface
proteins, hemagglutinin (HA) and neuraminidase (NA), resulting
in antigenic variation among circulating strains [10]. H5N1 viruses
have evolved rapidly whilst circulating among bird populations
since 1996, and changes to the H5 HA gene have been used as a
basis for phylogenetic characterization of a growing number of
distinct viral subgroups referred to as clades 0–9 [11]. The
constant evolution of viruses within each subgroup has generated
multiple second, third and fourth order clades defined by their
phylogenetic clustering and genetic distance [11,12]. Currently,
the majority of viruses circulating worldwide belong to clades 1
and 2, with clades 1.1, 2.1.3.2, 2.2.1, 2.2.2, 2.3.2.1, 2.3.4 and
2.3.4.2 responsible for recent human infections [13–16].
H5N1 viruses possess a hemagglutinin against which the human
population is immunologically naı̈ve [17,18], and thus, the World
Health Organization (WHO) prepares for the possibility of a
future H5N1 pandemic by coordinating the development of
candidate vaccine seed viruses from circulating strains [15]. The
rapid evolution of H5N1 viruses gives rise to changes in the HA
protein that result in altered antigenicity and prevent effective
long-term immunity from strain-specific vaccination [19]. To
account for this variation in antigenicity, the WHO has 22 H5N1
vaccine seed viruses currently available and 2 more in production
or pending safety evaluation [20].
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In addition to changes in antigenicity, changes in the receptor-
binding characteristics of circulating H5 viruses have also become
the focus of surveillance and pandemic preparedness efforts [21].
Influenza A viruses infect both avian and mammalian species
through binding of HA to sialic acid (Neu5Ac) moieties on the
surface of host cells, and viral host specificity is determined by both
viral HA structure and the type of host receptor [22]. Avian
influenza viruses preferentially bind a2-3-linked Neu5Ac receptors
present in the intestinal epithelia of birds, while human-adapted
viruses preferentially bind a2-6-linked Neu5Ac within the upper
airway [23–25]. Changes among H5N1 viruses which enhance
binding to the human-type Neu5Ac-a2-6-Gal linkage are consid-
ered a major factor in the generation of viruses with the capacity
for human to human transmission [26–28] and, as such, represent
potentially critical features of emerging strains with pandemic
potential.
Crystallographic analyses of hemagglutinins from distinct clades
of H5N1 viruses can provide important insight into changes in the
antigenic and receptor-binding properties of emerging strains.
However, structural information is currently limited to only clade
1 viruses, which emerged more than 8 years ago and whose
progeny are known to circulate only in the Mekong Delta regions
of Vietnam and Cambodia [29,30]. Herein, we report the
antigenic properties, receptor-binding specificities, and crystal
structures of hemagglutinins of three different H5N1 clades
responsible for recent fatal human infections in geographically
distinct areas: A/Egypt/N03072/2010 (Egypt10, clade 2.2.1), A/
Hubei/1/2010 (Hubei10, clade 2.3.2.1) and A/Anhui/1/2005
(Anhui05, clade 2.3.4) [31,32]. These viruses are phylogenetically
diverse and have distinct antigenic profiles, leading to their
selection by the WHO as pre-pandemic vaccine candidates [16].
Materials and Methods
Cloning, Expression and Purification of Recombinant HA
Proteins
All three proteins were derived from reverse genetics constructs
cloned from the parental viruses (A/Hubei/1/2010 (Hubei10,
clade 2.3.2.1); A/Egypt/N03072/2010 (Egypt10, clade 2.2.1); A/
Anhui/1/2005 (Anhui05, clade 2.3.4). The HA gene of each clone
was modified at the HA1/HA2 cleavage site to remove the
polybasic sequence (Table S2) [64]. A/Hubei/1/2010 (Hubei10,
clade 2.3.2.1) was received from CDC China as a genetically
modified clone, also lacking the polybasic cleavage motif. All three
constructs were cloned into the baculovirus transfer vector,
pAcGP67-A (BD Biosciences, San Jose, CA), and utilized a
thrombin site at the C-terminus of Anhui05 followed by a
trimerizing sequence (foldon) from the bacteriophage T4 fibritin
for generating functional trimers [65], and a His-Tag to aid
purification [66]. Transfection and virus amplification were
carried out as described previously [67,68].
Egypt10 and Hubei10 proteins were expressed from High
FiveTM cells (Life Technologies, Grand Island, NY) in 10-stack
CellSTACKTM culture chambers (Corning Inc., Corning, NY).
Soluble HA proteins were recovered from the culture supernatant
by His-Tag purification and subjected to thrombin cleavage and
gel filtration chromatography. Purified trimeric proteins were
buffer exchanged into 10 mM Tris-HCl, 150 mM NaCl, pH 8.0
and concentrated to 12 mg/ml for crystallization trials. At this
stage, the protein sample still contained the additional plasmid-
encoded residues at both the N (ADPG) and C terminus
(SGRLVPR). Purified Anhui05 protein (5 mg; Catalog No. FR-
86) was obtained from the Influenza Reagent Resource (http://
www.influenzareagentresource.org). This was subjected to throm-
bin digestion and purification as described for the other two
proteins and was concentrated to 10 mg/ml for crystallization
trials.
Crystallization and Data Collection
For all three proteins, initial crystallization trials were set up
using a TopazTM Free Interface Diffusion (FID) Crystallizer
system (Fluidigm Corporation, San Francisco, CA). Anhui05
crystals were observed in several conditions containing various
molecular weight PEG polymers. Following optimization, diffrac-
tion quality crystals were obtained at 20uC using a modified
method for micro-batch under oil [69], by mixing the protein with
a reservoir solution containing 20% PEG 4000 and 100 mM Tris-
HCl pH 7.8. Useable crystals of Hubei10 were produced using the
sitting drop vapor diffusion method at 20uC within a well
containing 0.5 ml protein solution at 12 mg/ml and an equal
volume of reservoir solution containing 20% PEG 2000 MME
and 100 mM Tris-HCl pH 7.0. Useable crystals Egypt10 were
produced using the sitting drop vapor diffusion method at 20uC in
a well containing 0.5 ml protein solution at 12 mg/ml and an
equal volume of reservoir solution containing 25% PEG 3350 and
100 mM Tris-HCl pH 8.5. Crystals were flash-cooled at 100 K.
Datasets were collected at the Argonne National Laboratory
Advanced Photon Source (APS) beamlines 22-ID at 100 K. Data
were processed with the DENZO-SACLEPACK suite [70].
Statistics for data collection and refinement are presented in
Table S1.
Structure Determination and Refinement
All model building and refinement was carried out using Coot
[71], Phenix [72] as well as REFMAC5 [73] using TLS refinement
[74]. Model validation was carried out using MolProbity [75]. H5
HA from Anhui05 (clade 2.3.4) HA crystallized in trigonal space
group P3 and the crystal structure was determined by molecular
replacement with Phaser [76], using PDB:2FK0 as search model,
to 2.7 Å resolution. Three monomers that each form one-third of
an independent crystallographic trimer occupy the asymmetric
unit with an estimated solvent content of 59% based on a
Matthews’ coefficient (Vm) of 3.01 Å3/Da. The three HA
monomers within the ASU are highly similar and all Ca atoms
superimpose with an RMSD of only 0.7 Å.
H5 HA from Egypt10 (clade 2.2.1) crystallized in trigonal space
group H3 and the crystal structure was determined by molecular
replacement with Phaser [76], using PDB:2FK0 as search model,
to 2.5 Å resolution. The crystallographic asymmetric unit (ASU)
contains 4 monomers (A/B, C/D, E/F and G/H), which are all
highly similar to each other (Ca atoms superimpose with an
RMSD of only 0.3 Å), with all significant differences between
monomers restricted to flexible loops, due to differential packing of
the molecules within the ASU. Of note, residues 125–141 form a
highly exposed loop that is disordered in 3 of the 4 molecules
within the ASU. This loop, which forms a component of the
conserved receptor-binding domain, is only visible within contin-
uous 2FO-FC electron density of monomer A/B.
HA from Hubei10 (clade 2.3.2.1) HA crystallized in monoclinic
space group C2 and the crystal structure was determined by
molecular replacement with Phaser [76], using PDB:2FK0 as
search model, to 2.6 Å resolution. The crystallographic ASU
contains one trimer. Each monomer in the trimer (A/B, C/D and
E/F) is highly similar to the others, with their Ca atoms
superimposing with an RMSD of only 0.4 Å.
Structures of Three H5 Hemagglutinins
PLOS ONE | www.plosone.org 2 September 2013 | Volume 8 | Issue 9 | e75209
Glycan Binding Analyses
Glycan microarray printing and recombinant HA analyses have
been described previously [30,48,53,68,77]. Imprinted slides were
produced under contract using the Consortium for Functional
Glycomics glycan library (CDC version 1 slides; see Table S1 for




4)GlcNAcb-biotin (6SLNLN-b), obtained from the Consortium
for Functional Glycomics (www.functionalglycomics.org) through
the resource request program, were coupled to streptavidin coated
biosensors (Fortebio Inc.). Recombinant HA was diluted to 1 mg/
ml (4.42 mM) trimer in kinetics buffer (PBS containing 0.02% (vol/
vol) Tween 20, 0.005% (vol/vol) sodium azide and 100 mg/ml
bovine serum albumin). Binding was analyzed by Bio-Layer
Interferometry (BLI) on an Octet Red instrument (Fortebio, Inc.)
according to the manufacturers instructions and data were
analyzed using the system software and fitted to a 1:1 binding
model.
Hemagglutination Inhibition Assay
Influenza A (H5N1) viruses were antigenically characterized in
the hemagglutination inhibition (HI) assay using post-infection
ferret antiserum. Wild-type viruses of A/Egypt/N03072/2010
(Egypt/10, clade 2.2.1), A/Anhui/1/2005 (Anhui/05, clade 2.3.4)
and A/Vietnam/1203/2004 (Viet/04) were inoculated into 10
day-old embryonated chicken eggs and allantoic fluid containing
virus was harvested from eggs within 48 hours [78]. CDC
Institutional Animal Care and Use Committee (IACUC) approval
was not required for virus propagation in embryonated chicken
eggs because all eggs were destroyed prior to hatching. All work
was carried out according to guidance from the Office of
Laboratory Animal Welfare (OLAW), National Institutes of
Health, who is responsible for implementation of the PHS Policy
Animal Welfare Act (7 U.S.C. Sections 2131–2159) and the Public
Health Service Policy on Humane Care and Use of Laboratory
Animals (http://grants.nih.gov/grants/olaw/faqs.htm#App_4).
The A/Hubei/1/2010 (Hubei10, clade 2.3.2) virus was a
reassortant, comprising the internal genes A/Puerto Rico/8/1934
(H1N1; PR8) in combination with HA and NA genes derived by
reverse genetics (RG) methods [64]. Clones for the HA and NA
genes were provided by CDC China as a genetically modified
clone, lacking the polybasic cleavage motif. Ferret antiserum was
generated by intranasal inoculation, boosting at day 14, with
$500 HA units of concentrated virus and Titermax as adjuvant.
To obtain concentrated virus, 5 ml of infected allantoic fluid was
subjected to ultracentrifugation (45,0006g at 4uC for 3 hours). The
virus pellet was re-suspended in 300 ml PBS and tested to confirm
titers of $500 HA units. After 14 days post-boost sera was
collected. Individual ferret sera corresponding to each virus tested
were generated in at least two animals (i.e. at least two separate lots
were produced for each virus). The homologous titer of each sera
was tested and confirmed to be within 2-fold of other lots
produced against the same virus. If a greater than 2-fold difference
in homologous titers was determined, these sera were not used in
the HI analysis. All ferret work was conducted in an Association
for Assessment and Accreditation of Laboratory Animal Care
International-accredited animal facility, under the guidance of the
Centers for Disease Control and Prevention’s Institutional Animal
Care and Use Committee. HI assays were performed using turkey
erythrocytes as previously described [78,79]. All work was
performed in a Biosafety Safety level 3 enhanced facility.
H5N1 Clade Sequence Analysis
Nucleotide sequences for the H5 hemagglutinins were obtained
from GISAID (www.gisaid.org), Genbank (www.ncbi.nlm.nih.
gov/genomes/FLU), and the WHO website (www.who.int/
influenza/gisrs_laboratory/h5n1_nomenclature) using a subset
(no outliers) of the annotated H5 dataset described in [80].
Sequence accession number, strain names, clade annotations, and
data sources are given in Supporting File 1 along with a GISAID
acknowledgement table. Sequences were aligned and trimmed
(JalView, [81]to the mature HA1 region (including cleavage site)
and samples less than 90% of the alignment length were removed
via a custom Perl script (available upon request). Alignments were
made using MAFFT [82] and MUSCLE [83] and a translated
consensus sequence for each clade was calculated using Geneious
Pro version 5.5.6 (http://www.geneious.com).
PDB Accession Codes
The atomic coordinates and structure factors of Anhui05,
Egypt10 and Hubei10 HA are available from the RCSB PDB
under accession codes 4 KWM, 4 KW1 and 4 KTH.
Results
Antigenic Properties of HPAI H5N1 Viruses from Distinct
Clades
Candidate influenza vaccine viruses are primarily selected based
upon differences in the antigenic properties of circulating strains,
as determined by the hemagglutination inhibition (HI) assay. To
assess the antigenic profiles of the Egypt10, Hubei10, and Anhui05
vaccine candidates, we compared the HI cross-reactivity of these
viruses to one another and to the well-characterized clade 1
candidate vaccine virus, A/Vietnam/1203/2004 (Viet04), using
strain-specific polyclonal ferret antisera. Comparison of the serum
HI titers of these phylogenetically diverse viruses [33] indicated
the extent to which they were antigenically related (see Table 1
and Table S1). Based on the two-way cross-reactive HI titers, a
majority of the viruses tested were $8-fold down when compared
to sera generated against heterologous viruses. An exception was
Egypt10 (clade 2.2.1), which was covered ,8-fold, compared to
homologous titers, by antisera against the three other viruses.
Conversely, however, the Egypt10 antisera produced a .8-fold
reduction in homologous versus heterologous titers relative to the
three other viruses (Table 1 and Table S1). Viet04 antigen had
reduced cross-reactivity with antisera from heterologous viruses,
but its antisera did consistently cross-react with Anhui05 and
Egypt10. Anhui05 and Hubei10 displayed more straight-forward
two-way patterns wherein 8-fold or greater reduction in cross-
reactivity was measured.
HI reactivity is primarily dependent upon the inhibition of
receptor-binding by antibodies that recognize the globular head
region of the HA1 subunit, and variation in the HI cross-reactivity
titers of viruses is attributed primarily to differences in surface-
exposed residues of the HA1 [34]. A comparison of the amino acid
sequence identity indicated that these H5N1 HAs share a high
degree of sequence homology (91–94%). Furthermore, the
number of changes among surface-exposed residues in the HA1
of each virus is consistently low, ranging from 9 between Anhui05
and Viet04, to 19 between Hubei10 and Viet04 (Table 1). These
findings highlight the fact that sequence identity across the surface
of the HA protein per se is an insufficient measure for determining
antigenic relatedness among these H5 clades and imply that
antigenicity is associated with only a small subset of residues.
Structures of Three H5 Hemagglutinins
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Crystal Structures of Clades 2.2.1, 2.3.2.1 and 2.3.4 HA
Proteins
To determine the structural consequences of evolutionary
changes among these diverse H5N1 viruses, we crystallized
recombinant HA (recHA) proteins from Egypt10, Hubei10, and
Anhui05. All three H5 recHA proteins were amplified from
template genes modified for vaccine production, whereby their
polybasic cleavage site at positions 320–325 had been removed
(Figure S1) [35]. The recHAs all crystallized as trimers and
diffraction datasets were collected from native protein crystals of
each HA, as described in the methods. All three H5 HAs exhibited
a high degree of amino acid sequence identity to Viet04 (,95%
across the entire HA), and the three crystal structures were
determined by the molecular replacement method, using the
trimeric structure of Viet04 HA (PDB:2FK0) as a search model
[36]. Data collection and refinement statistics are summarized in
Table S2. Amino acid residues in each structure are numbered
consecutively, according to the ectodomain fragments of the
mature HA1 and HA2 subunits, respectively.
The overall structures of the three H5 HAs are similar to that of
Viet04, comprising a trimer of HA0 protomers, each with a
globular head containing the receptor-binding site (RBS), a
vestigial esterase domain, and a membrane-proximal domain with
its distinctive, central helical stalk and HA1/HA2 cleavage site.
Although the three HAs were crystallized as the intact HA0 pre-
cleaved form, a lack of interpretable electron density for the
cleavage site in all three structures implied this region forms an
exposed and highly flexible loop that does not influence the
structure of the adjacent HA1 and HA2 domains. All three HAs
possess N-carbohydrates attached to Asn residues at glycosylation
sites within the HA1 subdomain. N-carbohydrates were clearly
visible within the electron density at three of four sites in Egypt10
(Asn11, Asn23 and Asn164; mature H5 HA numbering), at all four
glycosylation sites within Hubei10 (Asn11, Asn23, Asn165 and
Asn286) and at a single site in Anhui05 (Asn165). Furthermore, N-
carbohydrates were observed attached to the conserved Asn154 in
the HA2 of both Hubei10 and Anhui05. Occupancy at any given
N-glycosylation site varied among the different molecules within
the asymmetric unit in all three structures.
To assess structural variations among these HAs, we compared
the HA1/HA2 protomer of each structure with that of the Viet04
virus. All Ca atoms in the HA1/HA2 protomers of Egypt10,
Hubei10 and Anhui05 superimposed with Viet04 to give root
mean square deviations (RMSD) of only 0.86 Å, 0.74 Å and
1.04 Å, respectively, indicating a high degree of structural
homology in the configuration of these HAs (Figure 1A & Table
S3). All three structures revealed a similar canonical configuration
for the membrane-distal receptor-binding site (RBS). Highly
conserved residues (Tyr91, Trp149, His179, and Tyr191) formed
the base of the sialic acid binding pocket (Figure 1B), surrounded
by three highly-conserved structural elements: a 190-helix, a 220-
loop, and a 130-loop. A profound difference in the amino acid
sequence of the RBS in Egypt10 is a deletion of Leu129 coupled
with the substitution of Ile151Thr (del129/Thr151), a character-
istic found among the majority of circulating clade 2.2.1 viruses
isolated in Egypt [3] and reminiscent of the HA from the 1957
H2N2 pandemic strain [37]. The structural consequence of this
deletion/substitution combination is restricted to a minimal
rearrangement of residues 128 and 130. There was no perceived
effect on the overall conformation of the 130-loop and no change
in the association of Ser128 or Gly130 with Thr151 relative to the
other H5 structures (Figure 1C).
Table 1. Antigenic and amino acid sequence variation among different clades of H5N1 vaccine candidate viruses.
Viet04 (1) Anhui05 (2.3.4) Egypt10 (2.2.1) Hubei10 (2.3.2.1)
HA Antigen clade HI Titers (antisera)a
Viet04 1 285b $8c $8 ,8
Anhui05 2.3.4 ,8 718 $8 $8
Egypt10 2.2.1 ,8 ,8 3620 ,8
Hubei10d 2.3.2.1 $8 $8 $8 285
HA HA1% sequence identity (%)e
Viet04 1 100
Anhui05 2.3.4 94 100
Egypt10 2.2.1 93 93 100
Hubei10 2.3.2.1 91 92 91 100
HA % sequence identity of surface residues only (total # differences)f
Viet04 1 100
Anhui05 2.3.4 95 (9) 100
Egypt10 2.2.1 91 (15) 93 (12) 100
Hubei10 2.3.2.1 89 (19) 90 (16) 89 (18) 100
aHemagglutination inhibition (HI) titers were determined using turkey red blood cells.
bTiters for homologous antigen/antisera are shown with values underlined. Titers are presented as the geometric mean titers (GMT) calculated from five independent HI
tests.
cDifferences among strain-specific cross reactivity are quoted as dilutions relative to that of the end-point dilution value for the homologous antigen/sera response.
Viruses are considered antigenically diverse if titers are reported as $8-fold difference in two-way tests.
dOnly a reassortant virus for Hubei10 was used in assay. Others were wild type viruses.
eAmino acid sequence identities were calculated for the 267 residues of the HA1 structural domain (residues 34–300) of the mature HA, using CLUSTALX [84].
fSurface residue differences were quantified for the HA1 structural domain (residues 34–300) of the mature HA monomer. For this analysis, 166 of the 267 residues were
considered surface residues. The number of surface residue substitutions is given in parentheses.
doi:10.1371/journal.pone.0075209.t001
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Effect of Structural Changes on Antigenicity
The structures of antigenically diverse H5 HAs highlight
solvent-accessible residues unique to each strain that can give rise
to diversity in the humoral immune response. Compared to the
clade 1 Viet04 structure, residue substitutions among these three
viruses are restricted to 41 positions, of which only 29 are surface
exposed (see Table S4). The spatial distribution of these residues is
highlighted in Figure 2. Residue substitutions in the vicinity of the
membrane-distal RBS of HA may influence HI reactivity and
thereby impact the antigenic profile of the virus [38]. Residue
changes at the majority (17 of 29 residues) of these surface-exposed
positions are located in the membrane-distal region of the globular
HA1 and are likely, therefore, to influence HI (Figure 2A). Twelve
of these positions are structurally equivalent to the antigenic sites
recognized in human H1N1 HAs [39], and seven of these twelve,
including 140 and 141 (structurally equivalent to the Ca antigenic
site), 154, 155, 156 and 162 (Sa antigenic site), and 189 (Sb
antigenic site) contain multiple substitutions and represent the
predominant sites for antigenic variability among these viruses.
Significant differences in the size and charge of amino acid side
chains at positions 140, 141 and 189 at the exposed membrane-
distal tip of the globular HA1 domain produce distinct conforma-
tional arrangements in all four HA structures (illustrated in Figure
S2). Furthermore, the deletion of Leu129 in Egypt10 may produce
a distinct antigenic surface in the 130-loop of this virus. Notably,
this configuration of residues in the 130-loop is a characteristic
conserved among nearly all contemporary viruses in clade 2.2.1
(termed 2.2.1 group C), as well as a group of viruses in clade 2.2.
Substitutions at 12 positions located within the vestigial esterase
domain and elsewhere are distant from the RBS and are,
therefore, unlikely to significantly contribute to the antigenic
nature of these viruses in the context of HI reactivity (Figure 2A).
As observed in all other influenza viruses, the HA2 component is
more highly-conserved than the HA1 of these H5N1 viruses, with
comparatively little structural diversity and only three residue
substitutions among all four clades, which are unlikely to influence
HI reactivity.
Hence, the postulated dominant antigenic structures among
these four H5N1 viruses are, approximately, spatially equivalent to
established antigenic sites of H1N1 viruses in humans (Figure 2B)
[39]. Previous studies to establish the primary antigenic determi-
nants of H5 viruses among wild and domestic birds identified a
number of positions in and around the H1-equivalent sites
described here, by the generation of escape mutants [40], as well
as algorithm-based modeling of predictive antigenic sites [41]. To
assess the extent of variability at these antigenically significant
positions, we compared the equivalent H1N1 antigenic sites to the
consensus sequences of viruses from all 32 currently recognized
H5 clades (Figure 2B). Evidence for diversifying selective pressure
on this 50 residue subset of the exposed membrane-distal region of
HA1 is shown by the large number of substitutions within both
contemporary and historic H5N1 viruses.
Sialic Acid Binding Properties
Specificity of H5 HA for distinct linkages of sialic acid receptors
at the surface of epithelial cells is widely considered a major
determinant of host range and inter-species transmission [27].
Multiple studies have identified residue substitutions within and
Figure 1. Structural comparison between H5 hemagglutinins. (A) Structural alignment of Anhui05 (green), Egypt10 (blue) and Hubei10
(purple) onto Viet04 (yellow) reveals how structurally related these clades are. (B) Alignment of the receptor-binding site (RBS) reveals conserved
structural features and residues. (C) Compared to Viet04, a total of eleven residue differences in and around the RBS are present. Amino acid residues
in each structure are numbered consecutively according to the ectodomain fragment of the mature HA1 protein. *Deletion of Leu129 in Egypt10
produces a shift in the numbering of residues 129–324 in Egypt10 relative to structurally equivalent residues in Anhui05 and Hubei10.
doi:10.1371/journal.pone.0075209.g001
Structures of Three H5 Hemagglutinins
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around the receptor-binding site of H5 viruses that, either alone or
in combination with other mutations, were reported to increase
the infectivity for host cells bearing the human-type Neu5Ac-a2-6-
Gal linkage, as well as transmissibility and/or pathogenesis in
mammalian models [3,26,28,42–52]. Molecular analyses of glycan
recognition by multiple HA subtypes have revealed a complicated
interaction between sialylated multi-antennary oligosaccharides
and influenza viruses [53]. Advances in glycan array technology
allow the assessment of viral binding specificity to over 400 types of
carbohydrates, including more than 50 comprising either a2–3 or
a2-6-linked sialic acids [54]. Previously, this technology was used
to demonstrate that the carbohydrate-binding profile of Viet04
HA could be significantly varied through mutation of residues
within the receptor-binding site [36]. Anhui05, Egypt10 and
Hubei10 all contain distinct residue substitutions within the region
of the sialic acid binding site relative to Viet04, including
substitutions that have been associated with an increase in H5
viral recognition of a2–6 linkages (Figure 1C). Ala133 (present in
Hubei10) has been reported to enhance recognition of Neu5Ac-
a2-6-Gal [50], and the adjacent Ala134Val substitution (also
present Egypt10) was found to reduce preferential recognition of
Neu5Ac-a2-3-Gal to levels equivalent to Neu5Ac-a2-6-Gal [47].
An increase in Neu5Ac-a2-6 binding has been associated with
Lys189Arg (present in both Hubei10 and Egypt10) [48], and the
deletion of Leu129 coupled with the substitution Ile151Thr
(present in Egypt10), has been shown to increase viral binding to
Neu5Ac-a2-6-Gal and infection in the airway epithelia of humans
[3]. To assess the combined effect of these residue differences on
receptor specificity, we subjected these three H5 recHAs to glycan
microarray analysis and compared them to the recHA from
Viet04. Consistent with previous findings, the glycan-binding
profile of Viet04 confirmed preference for avian (a2–3) linkages,
including good affinity for glycans with sulfate on the 6 position of
the GlcNAc residue at the third position in the glycan chain
(Figure 3A, Table S5, glycan #5–8). While Anhui05 and Hubei10
both bound to a2–3 glycans in a comparable, but weaker profile to
Viet04, Egypt10 revealed a much-reduced binding profile to a2–3
glycans, with the strongest signals coming from sulfated (#5–8)
and fucosylated (#30–34) a2–3 sialosides (Figure 3B, 3C & 3D,
Table S5). Binding to human a2–6 receptors was minimal for all 4
recHAs tested; however, a weak binding to a2–6 sialylated N, N-
diacetyllactosediamine (LacDiNAc) (glycan #56) was observed for
Viet04 and Hubei10 (Figure 3A, 3D and Table S5), while
additional weak binding to a2–6 biantennary glycans (#42–45)
Figure 2. Structural variation among the different H5N1 clades. (A) Surface representation of the Hubei10 trimeric HA indicating the
positions of surface exposed residue substitutions among Clade 1 (Viet04), clade 2.3.4 (Anhui05), clade 2.2.1 (Egypt10) and clade 2.3.2.1 (Hubei10).
Positions containing single substitutions are colored cyan and positions containing multiple substitutions are colored magenta. (B) Amino acid
consensus sequences of H5N1 HA clades at positions equivalent to the HA antigenic sites, Ca, Cb, Sa and Sb, of human H1N1 viruses [39], are shown.
Clade 1 (Viet04), clade 2.3.4 (Anhui05), clade 2.2.1 (Egypt10) and clade 2.3.2.1 (Hubei10) are highlighted in red. Structural positions of these equivalent
sites are highlighted on the Hubei10 trimeric structure (Ca; pale yellow, Cb; wheat, Sa; pale green, Sb; pale blue). Asparagine residues that are
potentially N-glycosylated are colored orange.
doi:10.1371/journal.pone.0075209.g002
Structures of Three H5 Hemagglutinins
PLOS ONE | www.plosone.org 6 September 2013 | Volume 8 | Issue 9 | e75209
was observed for Hubei10, with some minimal interaction
observed for Viet04, Egypt10 and Anhui05.
The observed binding of the panel of HAs to a2–6 LacDiNAc
was further analyzed by Bio-Layer Interferometry (BLI). This label
free technology was used to measure recombinant HA binding to
biotinylated glycans, Neu5Ac(a2–3) Gal(b1–4) Glc-biotin (3SLN-
b), Neu5Ac(a2–3)-Gal(b1–4)-GlcNAc(b1–3)-Gal(b1–4)-GlcNAcb-
biotin (3SLNLN-b) and Neu5Ac(a2–6)-Gal(b1–4)-GlcNAc(b1–3)-
Gal(b1–4)-GlcNAcb-biotin (6SLNLN-b) preloaded onto streptavi-
din coated biosensors. Results for both Viet04 and Anhui05
proteins confirmed those of the glycan microarray, in that binding
to 6SLNLN-b could be detected in real time (Figure S3). The
weaker binding signals observed for 6SLNLN-b in the microarrays
(Figures 3A & 3D) can be explained by the higher dissociation
rates (1.6622.56) compared to 3SLNLN-b (Table S6). Thus,
despite these HAs having a number of changes that were
previously reported to increase viral attachment to human-type
receptors, the combinations of these changes in Anhui05, Hubei10
and Egypt10 do not appear to increase binding to human-type
(a2–6) sialic acid linkages under these experimental conditions.
Discussion
Ongoing surveillance of HPAI H5N1 viruses has facilitated the
early detection of changes in emerging strains, and significant
efforts have been made to identify changes among the increasingly
diverse pool of viral genotypes that may lead to increased host
range and/or pathogenesis [55]. In view of the increasing diversity
among circulating strains, interpretation of the antigenic changes
observed in novel HA genes is important to ensure pre-pandemic
vaccine candidates will offer sufficient protection in the event of a
H5N1 pandemic. This study provides important insight into how
changes in the receptor-binding site of circulating H5N1 viruses
correlate to receptor specificity and identifies antigenically
dominant structures at the surface of the H5 HA.
A primary significance of this study lies in the interpretation of
how the evolution of H5N1 HPAI viruses relates to changes in
antigenicity. Our data highlight the fact that the phylogenetic
grouping of H5 viruses into distinct clades based on similarities at
the amino acid sequence level is inadequate by itself for
approximating antigenic relatedness, as residues that determine
antigenicity are localized compared to the longer sequence data
used in clade assignment. [56]. Moreover, structures of the
antigenically distinct H5 HAs presented here enabled the
Figure 3. Receptor specificity of H5 recHAs. Glycan microarray analysis of recombinant Viet04 HA (A), Anhui05 (B), Egypt10 (C) and Hubei10 (D).
Colored bars highlight glycans that contain a2–3 Neu5Ac (blue) and a2–6 Neu5Ac (red), a2–6/a2–3 mixed Neu5Ac (purple), N-glycolyl Neu5Ac
(green), a2–8 Neu5Ac (brown), b2–6 and 9-O-acetyl Neu5Ac (yellow), and non-Neu5Ac (grey). Error bars reflect the standard error in the signal for six
independent replicates on the array. The structures of each of the numbered glycans are found in Table S5.
doi:10.1371/journal.pone.0075209.g003
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identification of the dominant antigenic structures, at positions
140, 141, 154–156, 162 and 189, which contribute to the strain-
specific antigenic profiles of these viruses. N-carbohydrates
attached to Asn154 of Viet04 and Anhui05 mask the vicinal Sb-
equivalent antigenic structures from immune recognition and
represent an additional factor affecting antigenic variation among
these viruses [40,49]. The substitution Asn154Asp, which results in
loss of this carbohydrate among clade 2.2.1 and 2.3.2.1 viruses,
leaves the proximal residues exposed and potentially subject to
selective immune pressure, thereby enhancing antigenic diversity
among Egypt10 and Hubei10. Identification of these antigenic
structures provides important information about antigenic diver-
sity among circulating H5 HPAI viruses and can assist in
interpreting the significance of amino acid substitutions in
emerging strains.
Firstly, our data suggests that substitutions at the solvent-
exposed positions 140, 141, 154–156, 162 and 189 of H5 HA
correlate with changes in the antigenic signature of the virus,
reminiscent of the spatially equivalent antigenic sites among H1
HAs circulating in the human population. Second, the H5 HA
structures reported here represent a growing body of structural
information for this important group of influenza A viruses, and as
more H5 HA structures from antigenically diverse viruses become
available, a more robust footprint of the primary antigenic sites
will emerge to assist in identifying emerging strains with increased
potential for antigenic diversity. Third, the identification of regions
among H5 viruses that are highly prone to antigenic pressure may
also improve genetic distance measures by differently weighting
these antigenic regions when making clade determinations based
on clustering of H5 viruses. Finally, these structural data could also
aid in the development of bioinformatics software and/or
databases to help surveillance efforts, monitoring how changes in
avian circulating viruses correlate with changes which could lead
to antigenic differences in human viruses.
Another contribution of this study is the comprehensive analysis
of receptor specificities for three H5 HPAI recombinant HA
proteins, both by glycan array and BLI techniques. An H5 HPAI
capable of transmission between humans may be expected to
possess substitutions within the RBS related to enhanced binding
to the a2-6-linked receptor present within the human airway.
None of the recHAs analyzed in this study exhibited preferential
glycan-binding specificity for the a2–6 Neu5Ac linkage. Of note,
clade 2.2.1 viruses that have recently emerged in Egypt exhibit
many changes thought to enhance inter-species transmissibility
and replication among mammalian hosts and are of particular
concern [3]. Indeed, since 2009, approximately 50% of the total
human cases of H5N1 infection worldwide have occurred in Egypt
(see WHO website for regularly updated statistics). How might the
apparently enhanced pathogenesis and inter-species transmissibil-
ity of these viruses be explained? Our receptor-binding analyses
determined that Egypt10 recHA had no increase in a2–6 binding
relative to the clade 1 Viet04 recHA (Figure 3C), although this HA
did exhibit a substantial reduction in overall a2–3 binding, which
may influence the pathogenesis or transmissibility of the Egypt10
virus.
Viruses belonging to the H1, H2 and H3 groups differ in
species-specificity by as little as two amino acid substitutions [57–
59], however, factors controlling host specificity remain largely
ambiguous in the context of HPAI H5 viruses [26,27]. Although
enhanced recognition of a2–6 sialosides is required for effective
transmission of HPAI viruses among humans, amino acid
substitutions observed to enhance viral pathogenesis and replica-
tion in mammals are not restricted to those within the receptor-
binding site [28,60]. Several studies have identified changes in H5
HAs at a distance from the RBS associated with enhanced inter-
species transmission, as well as replication and pathogenesis of
HPAI viruses in non-avian hosts. Asp94Asn (present in Anhui05,
Egypt10, Hubei10) and Met227Ile (present in Hubei10) are both
located at a distance from the RBS and have been implicated in
enhanced receptor specificity for a2–6 sialosides and enhanced
viral infectivity of Viet04 in mammalian cells [28,60]. Such
changes may influence the association of HA monomers; residue
substitutions in the region of the hydrophobic fusion peptide have
been shown to influence the pH of membrane fusion and the
overall stability of the viral HA, which may play a role in host
determination. Likewise, the conserved change at Pro217Ser,
located near the RBS at the monomer/monomer interface is also
unlikely to contribute to antigenicity, but may be retained due to
enhanced stability in the HA trimer. Notably, Pro is retained at
this position among seasonal and ancestral H1 HAs, suggesting a
species-specific preference.
N-glycosylation also represents an indirect means to alter the
receptor function of H5 viruses and has been inversely correlated
with the broadness of HA receptor specificity [61,62]. Steric
hindrance of HA/receptor interactions by N-glycans may be
capable of changing HA receptor specificity for the distinct
topology of a2–6 and a2–3 linked sialosides [22,48]. Likewise, the
removal of N-glycosylation in the region of the RBS has been
associated with increased viral transmission, replication, and
pathogenicity [26,27,49]. Finally, it must be recognized that our
data relate to recHA binding to glycans on an array, where the
avidity and kinetics of the interaction may differ from those at the
host/viral interface. Moreover, it is also important to recognize the
significance of other genetic components, which function in
concert with the viral surface proteins, to potentially influence the
impact of receptor-binding specificity in contributing towards the
pathogenesis, infectivity and host range determination of HPAI
viruses [46,63].
Supporting Information
Figure S1 Vaccine H5 HA cleavage site comparison.
Sequence of (A) Anhui05, (B) Egypt10 and (C) Hubei10 H5 HAs
were compared to their wild type counterparts. The polybasic
cleavage site in the wild type virus sequence is boxed. Residues
highlighted in cyan could not be built in the three models reported
here, due to poor density in this region.
(DOCX)
Figure S2 Structural bases for antigenic variation
among vaccine candidate viruses. Topological and electro-
static changes at positions surrounding the receptor-binding site
are indicated on a molecular surface representation of (A) Viet04,
(B) Anhui05, (C) Egypt10 and (D) Hubei10. The absence of
Leu129 in Egypt10 (c) results in a more flattened, open
conformation in the 130 loop relative to the other four viruses.
The N-carbohydrate attached to Asn154 of Anhui05 (a) and
Viet04 (b) has been removed for clarity.
(TIF)
Figure S3 Kinetic binding analysis of (A) Viet04, (B)
Anhui05, (C) Egypt10 and (D) Hubei10 recombinant
HAs. The binding kinetics to specific biotinylated glycans (3SLN-
b, 3SLNLN-b, and 6SLNLN-b), immobilized onto biosensors,
were analyzed by BLI (A, B, C and D).
(TIF)
Table S1 Results of multiple HI Assays to determine
cross-reactivity of Viet04, Anhui05, Egypt10 and Hu-
bei10 against strain-specific ferret anti-sera.
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(DOCX)
Table S2 Data collection and refinement statistics for
the Anhui05, Egypt10 and Hubei10 crystal structures.
(DOCX)
Table S3 RMSD (Å) comparison for the HA1 and HA2
domains of each HA to previously reported clade 1,
Viet04.
(DOCX)
Table S4 Residue differences among Anhui05, Egypt10
and Hubei10 compared to Viet04. (A) Changes among
surface residues, exposed to immune surveillance. (B) Substituted
residues that do not have solvent accessible side chains. Positions
within antigenic sites are asindicated.
(DOCX)
Table S5 Glycan microarray differences between
Viet04, Anhui05, Egypt10 and Hubei10. The color coding
in the left hand column reflects the same coloring scheme used in
Figure 3. Significant binding of samples to glycans were
qualitatively estimated based on relative strength of the signal
for the data shown in the figure; Fluorescence Intensity .20000
(+++), 10000–19999 (++), 5000–9999 (+), ,2500 (nb). Different
categories of glycans on the array are color-coded in column 1 as
follows: No color, sialic acid; blue, a2–3 sialosides; red, a2–6
sialosides, violet, mixed a2–3/a2–6 biantennaries; green, N-
glycolylneuraminic acid-containing glycans; brown, a2–8 linked
sialosides; pink, b2–6 linked and 9-O-acetylated sialic acids; grey,
asialo glycans.
(DOCX)
Table S6 Kinetics results for glycan binding to Viet04,
Anhui05, Egypt10 and Hubei10 recombinant HAs.
(DOCX)
Acknowledgments
The authors would like to thank the WHO Global Influenza Surveillance
and Response System (GISRS) and all submitting laboratories who have
deposited their H5N1 HA sequences to the GISAID database. We also
thank Limei Chen (CDC), Wen-Pin Tzeng (CDC), Yumiko Matsuoka
(NIH) and Dr. Yuelong Shu (Director of the WHO Collaborating Center
for Influenza Reference and Research at the China Center for Disease
Control) for kindly providing the reverse genetics plasmids used as pcr
templates to generate the HA expression clones. Recombinant H5 HA with
hexa-histidine tag, from Influenza A/Anhui/1/2005 (H5N1), FR-86, was
obtained through the Influenza Reagent Resource (http://www.
influenzareagentresource.org). The authors would also like to thank the
staff of SER-CAT sector 22 for their help in data collection. We also thank
the CFG for the supplying the biotinylated glycans used here, through their
resource request program. The findings and conclusions in this report are
those of the authors and do not necessarily represent the views of the
Centers for Disease Control and Prevention or the Agency for Toxic
Substances and Disease Registry. The atomic coordinates and structure
factors for Anhui05, Hubei10 and Egypt10 HA have been deposited in the
RCSB PDB under accession codes AAAA, BBBB, and CCCC,
respectively. Alexander Klimox, PhD passed away on February 5th, 2013.
Author Contributions
Conceived and designed the experiments: DAS HY ALB SSS PJC JCC
CTD JS. Performed the experiments: DAS HY ALB SSS PJC JCC CTD
JS. Analyzed the data: DAS HY ALB SSS PJC JCC CTD ROD JMV AIK
JS. Wrote the paper: DAS HY ALB SSS PJC JCC CTD ROD JMV AIK
JS.
References
1. Jia N, de Vlas SJ, Liu YX, Zhang JS, Zhan L, et al. (2009) Serological reports of
human infections of H7 and H9 avian influenza viruses in northern China. J Clin
Virol 44: 225–229.
2. CDC (2012) Notes from the Field: Highly Pathogenic Avian Influenza A (H7N3)
Virus Infection in Two Poultry Workers - Jalisco, Mexico, July 2012. MMWR
Morb Mortal Wkly Rep 61: 726–727.
3. Watanabe Y, Ibrahim MS, Ellakany HF, Kawashita N, Mizuike R, et al. (2011)
Acquisition of human-type receptor binding specificity by new H5N1 influenza
virus sublineages during their emergence in birds in Egypt. PLoS Pathog 7:
e1002068.
4. WHO (2012) Cumulative number of confirmed human cases of avian influenza
A(H5N1) reported to WHO. http://www.who.int/influenza/human_animal_
interface/H5N1_cumulative_table_archives/en/index.html. Accessed 2013 Aug
16.
5. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, et al. (2005)
Probable person-to-person transmission of avian influenza A (H5N1).
N Engl J Med 352: 333–340.
6. WHO (2006) Avian influenza situation in Indonesia - update 16. http://www.
who.int/csr/don/2006_05_31/en/index.html. Accessed 2013 Aug 16.
7. Wang H, Feng Z, Shu Y, Yu H, Zhou L, et al. (2008) Probable limited person-
to-person transmission of highly pathogenic avian influenza A (H5N1) virus in
China. Lancet 371: 1427–1434.
8. WHO (2008) Human cases of avian influenza A (H5N1) in North-West Frontier
Province, Pakistan, October-November 2007. Wkly Epidemiol Rec 83: 359–
364.
9. Fauci AS (2006) Seasonal and pandemic influenza preparedness: science and
countermeasures. J Infect Dis 194 Suppl 2: S73–76.
10. Fitch WM, Leiter JM, Li XQ, Palese P (1991) Positive Darwinian evolution in
human influenza A viruses. Proc Natl Acad Sci U S A 88: 4270–4274.
11. WHO_OIE_FAO_H5N1_Evolution_Working_Group (2008) Toward a unified
nomenclature system for highly pathogenic avian influenza virus (H5N1). Emerg
Infect Dis 14: e1.
12. WHO_OIE_FAO_H5N1_Evolution_Working_Group (2009) Continuing prog-
ress towards a unified nomenclature for the highly pathogenic H5N1 avian
influenza viruses: divergence of clade 2.2 viruses. Influenza Other Respi Viruses
3: 59–62.
13. Yang JX, Ju LW, Jiang LF, Shi Q, Jiang QW, et al. (2009) [Type and subtype
distribution of influenza virus and genetic evolution of hemagglutinin in
Shanghai area in duration of 2004–2008]. Zhonghua Yu Fang Yi Xue Za Zhi
43: 305–308.
14. WHO (2010) Antigenic and genetic characteristics of influenza A(H5N1)and
influenza A(H9N2) viruses and candidate vaccine viruses developed for potential
use in human vaccines. Wkly Epidemiol Rec 85: 418–424.
15. WHO (2011) Antigenic and genetic characteristics of influenza A(H5N1) and
influenza A(H9N2) viruses for development of candidate vaccines viruses for
pandemic preparedness - February 2011. Wkly Epidemiol Rec 86: 93–100.
16. WHO (2012) Antigenic and genetic characteristics of zoonotic influenza viruses
and development of candidate vaccine viruses for pandemic preparedness. Wkly
Epidemiol Rec 87: 97–108.
17. Tang JW, Ngai KL, Chan PK (2008) Lack of cross-immune reactivity against
influenza H5N1 from seasonal influenza vaccine in humans. J Med Virol 80:
1992–1996.
18. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and
immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
N Engl J Med 354: 1343–1351.
19. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, et al. (2008) Influenza
vaccine strain selection and recent studies on the global migration of seasonal
influenza viruses. Vaccine 26 Suppl 4: D31–34.
20. World Health Orgnization (2013) Candidate vaccine viruses and potency testing
reagents for influenza A(H5N1). Geneva.
21. Peiris JS, Poon LL, Guan Y (2012) Public health. Surveillance of animal
influenza for pandemic preparedness. Science 335: 1173–1174.
22. Chandrasekaran A, Srinivasan A, Raman R, Viswanathan K, Raguram S, et al.
(2008) Glycan topology determines human adaptation of avian H5N1 virus
hemagglutinin. Nat Biotechnol 26: 107–113.
23. Ito T, Couceiro JN, Kelm S, Baum LG, Krauss S, et al. (1998) Molecular basis
for the generation in pigs of influenza A viruses with pandemic potential. J Virol
72: 7367–7373.
24. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk H-D (2004)
Human and avian influenza viruses target different cell types in cultures of
human airway epithelium. Proc Natl Acad Sci USA 101: 4620–4624.
25. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, et al. (2006) Avian flu:
influenza virus receptors in the human airway. Nature 440: 435–436.
26. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, et al. (2012)
Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336:
1534–1541.
27. Imai M, Kawaoka Y (2012) The role of receptor binding specificity in
interspecies transmission of influenza viruses. Curr Opin Virol 2: 160–167.{ Deceased
Structures of Three H5 Hemagglutinins
PLOS ONE | www.plosone.org 9 September 2013 | Volume 8 | Issue 9 | e75209
28. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, et al. (2012) Experimental
adaptation of an influenza H5 HA confers respiratory droplet transmission to a
reassortant H5 HA/H1N1 virus in ferrets. Nature 486: 420–428.
29. Russell RJ, Stevens DJ, Haire LF, Gamblin SJ, Skehel JJ (2006) Avian and
human receptor binding by hemagglutinins of influenza A viruses. Glycoconj J
23: 85–92.
30. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, et al. (2006)
Haemagglutinin mutations responsible for the binding of H5N1 influenza A
viruses to human-type receptors. Nature 444: 378–382.
31. Wan XF, Dong L, Lan Y, Long LP, Xu C, et al. (2011) Indications that live
poultry markets are a major source of human H5N1 influenza virus infection in
China. J Virol 85: 13432–13438.
32. Younan M, Poh MK, Elassal E, Davis T, Rivailler P, et al. (2013)
Microevolution of highly pathogenic avian influenza A(H5N1) viruses isolated
from humans, Egypt, 2007–2011. Emerg Infect Dis 19: 43–50.
33. WHO OIE FAO H5N1 Evolution Working Group (2012) Continued evolution
of highly pathogenic avian influenza A (H5N1): Updated nomenclature.
Influenza Other Respi Viruses 6: 1–5.
34. Lee MS, Yang CF (2003) Cross-reactive H1N1 antibody responses to a live
attenuated influenza vaccine in children: implication for selection of vaccine
strains. J Infect Dis 188: 1362–1366.
35. Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, et al. (2003) Evaluation of
a genetically modified reassortant H5N1 influenza A virus vaccine candidate
generated by plasmid-based reverse genetics. Virology 305: 192–200.
36. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, et al. (2006)
Structure and receptor specificity of the hemagglutinin from an H5N1 influenza
virus. Science 312: 404–410.
37. Liu J, Stevens DJ, Haire LF, Walker PA, Coombs PJ, et al. (2009) Structures of
receptor complexes formed by hemagglutinins from the Asian Influenza
pandemic of 1957. Proc Natl Acad Sci U S A 106: 17175–17180.
38. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus
entry: the influenza hemagglutinin. Annu Rev Biochem 69: 531–569.
39. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W (1982) The antigenic
structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell
31: 417–427.
40. Kaverin NV, Rudneva IA, Govorkova EA, Timofeeva TA, Shilov AA, et al.
(2007) Epitope mapping of the hemagglutinin molecule of a highly pathogenic
H5N1 influenza virus by using monoclonal antibodies. J Virol 81: 12911–12917.
41. Cai Z, Ducatez MF, Yang J, Zhang T, Long LP, et al. (2012) Identifying
Antigenicity-Associated Sites in Highly Pathogenic H5N1 Influenza Virus
Hemagglutinin by Using Sparse Learning. J Mol Biol 422: 145–155.
42. Auewarakul P, Suptawiwat O, Kongchanagul A, Sangma C, Suzuki Y, et al.
(2007) An avian influenza H5N1 virus that binds to a human-type receptor.
J Virol 81: 9950–9955.
43. Gao Y, Zhang Y, Shinya K, Deng G, Jiang Y, et al. (2009) Identification of
amino acids in HA and PB2 critical for the transmission of H5N1 avian
influenza viruses in a mammalian host. PLoS Pathog 5: e1000709.
44. Ilyushina NA, Govorkova EA, Gray TE, Bovin NV, Webster RG (2008)
Human-like receptor specificity does not affect the neuraminidase-inhibitor
susceptibility of H5N1 influenza viruses. PLoS Pathog 4: e1000043.
45. Kongchanagul A, Suptawiwat O, Kanrai P, Uiprasertkul M, Puthavathana P, et
al. (2008) Positive selection at the receptor-binding site of haemagglutinin H5 in
viral sequences derived from human tissues. J Gen Virol 89: 1805–1810.
46. Maines TR, Chen LM, Van Hoeven N, Tumpey TM, Blixt O, et al. (2011)
Effect of receptor binding domain mutations on receptor binding and
transmissibility of avian influenza H5N1 viruses. Virology 413: 139–147.
47. Naughtin M, Dyason JC, Mardy S, Sorn S, von Itzstein M, et al. (2011)
Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambo-
dian clade 1 highly pathogenic H5N1 influenza virus. Antimicrob Agents
Chemother 55: 2004–2010.
48. Stevens J, Blixt O, Chen LM, Donis RO, Paulson JC, et al. (2008) Recent avian
H5N1 viruses exhibit increased propensity for acquiring human receptor
specificity. J Mol Biol 381: 1382–1394.
49. Wang W, Lu B, Zhou H, Suguitan AL, Jr., Cheng X, et al. (2010) Glycosylation
at 158N of the hemagglutinin protein and receptor binding specificity
synergistically affect the antigenicity and immunogenicity of a live attenuated
H5N1 A/Vietnam/1203/2004 vaccine virus in ferrets. J Virol 84: 6570–6577.
50. Yang ZY, Wei CJ, Kong WP, Wu L, Xu L, et al. (2007) Immunization by avian
H5 influenza hemagglutinin mutants with altered receptor binding specificity.
Science 317: 825–828.
51. Yen H-L, Aldridge JR, Boon ACM, Ilyushina NA, Salomon R, et al. (2009)
Changes in H5N1 influenza virus hemagglutinin receptor binding domain affect
systemic spread. Proc Natl Acad Sci USA 106: 286–291.
52. CDC (2012) H5N1 Genetic Changes Inventory: A Tool for Influenza
Surveillance and Preparedness. http://wwwcdcgov/flu/avianflu/h5n1-genetic-
changeshtm.
53. Stevens J, Blixt O, Glaser L, Taubenberger JK, Palese P, et al. (2006) Glycan
microarray analysis of the hemagglutinins from modern and pandemic influenza
viruses reveals different receptor specificities. J Mol Biol 355: 1143–1155.
54. Blixt O, Hoffmann J, Svenson S, Norberg T (2008) Pathogen specific
carbohydrate antigen microarrays: a chip for detection of Salmonella O-antigen
specific antibodies. Glycoconj J 25: 27–36.
55. Guan Y, Poon LL, Cheung CY, Ellis TM, Lim W, et al. (2004) H5N1 influenza:
a protean pandemic threat. Proc Natl Acad Sci U S A 101: 8156–8161.
56. Wu WL, Chen Y, Wang P, Song W, Lau SY, et al. (2008) Antigenic profile of
avian H5N1 viruses in Asia from 2002 to 2007. J Virol 82: 1798–1807.
57. Rogers GN, Paulson JC, Daniels RS, Skehel JJ, Wilson IA, et al. (1983) Single
amino acid substitutions in influenza haemagglutinin change receptor binding
specificity. Nature 304: 76–78.
58. Connor RJ, Kawaoka Y, Webster RG, Paulson JC (1994) Receptor specificity in
human, avian, and equine H2 and H3 influenza virus isolates. Virology 205: 17–
23.
59. Tumpey TM, Maines TR, Van Hoeven N, Glaser L, Solorzano A, et al. (2007)
A two-amino acid change in the hemagglutinin of the 1918 influenza virus
abolishes transmission. Science 315: 655–659.
60. Su Y, Yang HY, Zhang BJ, Jia HL, Tien P (2008) Analysis of a point mutation in
H5N1 avian influenza virus hemagglutinin in relation to virus entry into live
mammalian cells. Arch Virol 153: 2253–2261.
61. de Vries RP, de Vries E, Bosch BJ, de Groot RJ, Rottier PJ, et al. (2010) The
influenza A virus hemagglutinin glycosylation state affects receptor-binding
specificity. Virology 403: 17–25.
62. Wang CC, Chen JR, Tseng YC, Hsu CH, Hung YF, et al. (2009) Glycans on
influenza hemagglutinin affect receptor binding and immune response. Proc
Natl Acad Sci U S A 106: 18137–18142.
63. Chen LM, Blixt O, Stevens J, Lipatov AS, Davis CT, et al. (2012) In vitro
evolution of H5N1 avian influenza virus toward human-type receptor specificity.
Virology 422: 105–113.
64. O’Neill E, Donis RO (2009) Generation and characterization of candidate
vaccine viruses for prepandemic influenza vaccines. Curr Top Microbiol
Immunol 333: 83–108.
65. Frank S, Kammerer RA, Mechling D, Schulthess T, Landwehr R, et al. (2001)
Stabilization of short collagen-like triple helices by protein engineering. J Mol
Biol 308: 1081–1089.
66. Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, et al. (2004)
Structure of the uncleaved human H1 hemagglutinin from the extinct 1918
influenza virus. Science 303: 1866–1870.
67. Yang H, Carney P, Stevens J (2010) Structure and Receptor binding properties
of a pandemic H1N1 virus hemagglutinin. PLoS Curr: RRN1152.
68. Yang H, Chen LM, Carney PJ, Donis RO, Stevens J (2010) Structures of
receptor complexes of a North American H7N2 influenza hemagglutinin with a
loop deletion in the receptor binding site. PLoS Pathog 6: e1001081.
69. Chayen NE, Shaw-Steward PD, Blow DM (1992) Microbatch crystallization
under oil – a new technique allowing many small volume crystallization
experiments J Cryst Growth 122: 176–180.
70. Otwinowski A, Minor W (1997) Processing of X-ray diffraction data collected in
oscillation mode. Meothds in Enzymology 276: 307–326.
71. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics.
Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
72. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010)
PHENIX: a comprehensive Python-based system for macromolecular structure
solution. Acta Crystallogr D Biol Crystallogr 66: 213–221.
73. CCP4 (1994) The CCP4 suite: programs for protein crystallography. Acta
Crystallogr D Biol Crystallogr 50: 760–763.
74. Winn MD, Isupov MN, Murshudov GN (2001) Use of TLS parameters to model
anisotropic displacements in macromolecular refinement. Acta Crystallogr D Biol
Crystallogr 57: 122–133.
75. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, et al. (2007)
MolProbity: all-atom contacts and structure validation for proteins and nucleic
acids. Nucleic Acids Res 35: W375–383.
76. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ (2005) Likelihood-
enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 61: 458–
464.
77. Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, et al. (2004) Printed
covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc
Natl Acad Sci U S A 101: 17033–17038.
78. WHO (2011) Manual for the laboratory diagnosis and virological surveillance of
Influenza. WHO Global Influenza Surveillance Network: 48–57.
79. Klimov A, Balish A, Veguilla V, Sun H, Schiffer J, et al. (2012) Influenza virus
titration, antigenic characterization, and serological methods for antibody
detection. Methods Mol Biol 865: 25–51.
80. Shepard SS, Davis CT, Bahl J, Rivailler P, York IA, et al. (2013) LABEL: fast
and accurate lineage assignment with assessment of H5N1 and H9N2 influenza
A hemagglutinins. http://137.132.104.5/label/. Accessed 2013 Aug 16.
81. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ (2009) Jalview
Version 2–a multiple sequence alignment editor and analysis workbench.
Bioinformatics 25: 1189–1191.
82. Katoh K, Misawa K, Kuma K, Miyata T (2002) MAFFT: a novel method for
rapid multiple sequence alignment based on fast Fourier transform. Nucleic
Acids Res 30: 3059–3066.
83. Edgar RC (2004) MUSCLE: multiple sequence alignment with high accuracy
and high throughput. Nucleic Acids Res 32: 1792–1797.
84. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG (1997) The
CLUSTAL_X windows interface: flexible strategies for multiple sequence
alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876–4882.
Structures of Three H5 Hemagglutinins
PLOS ONE | www.plosone.org 10 September 2013 | Volume 8 | Issue 9 | e75209
